Eyenuk Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Employees
  • 21
Employees
  • Latest Deal Type
  • Later Stage VC
  • (Upcoming)
  • Investors
  • 2

Eyenuk General Information

Description

Developer of artificial intelligence (AI) medical technology and services intended for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. The company offers real-world AI Eye Screening and AI Predictive Biomarkers for risk assessment and disease surveillance, enabling patients to screen their eyes to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk, and Alzheimer's disease.

Contact Information

Website
www.eyenuk.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Laboratory Services (Healthcare)
Other Healthcare Services
Primary Office
  • 5850 Canoga Avenue
  • Suite 250, Woodland Hills
  • Los Angeles, CA 91367
  • United States
+1 (818) 000-0000

Eyenuk Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Eyenuk Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Later Stage VC 31-Dec-2021 Upcoming Generating Revenue
12. Later Stage VC 20-Jul-2021 00.00 000.00 Completed Generating Revenue
11. Grant 01-Jul-2020 00000 00.000 Completed Generating Revenue
10. Grant 30-Sep-2019 00000 00.000 Completed Generating Revenue
9. Grant 01-Jun-2018 00.00 00.000 Completed Generating Revenue
8. Seed Round 30-Apr-2018 00.000 00.000 000.00 Completed Generating Revenue
7. Seed Round 31-Oct-2017 00.00 000 00.00 Completed Clinical Trials - General
6. Grant 01-Aug-2016 000 00.00 Completed Clinical Trials - General
5. Seed Round 19-Jul-2016 $1.5M $1.5M 000 Completed Clinical Trials - General
4. Grant 01-Jan-2016 $7M Completed Product In Beta Test
To view Eyenuk’s complete valuation and funding history, request access »

Eyenuk Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series S-2 000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series S-1 000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series S 348,547 $0.000100 6% $4.49 $4.49 1x $4.49 14.48%
To view Eyenuk’s complete cap table history, request access »

Eyenuk Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of artificial intelligence (AI) medical technology and services intended for autonomous disease detection and
Diagnostic Equipment
Los Angeles, CA
21 As of 2021
000.00
0000000000 0

00000000

enderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupi
0000000000 000000000
Padua, Italy
00000
00.00 0000-00-00
000000&0 00000

00000000

lit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, qui
0000000000 000000000
Pensacola, FL
00 As of 0000
000.00
000000000 - 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eyenuk Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CenterVue Formerly VC-backed Padua, Italy 00000 000000&0 00000
00000000000 000000 Venture Capital-Backed Pensacola, FL 00 000.00 000000000 - 000.00
0000000 0000000000 Venture Capital-Backed Coralville, IA 00 0000 000000 0 0000
0000000 Private Equity-Backed Fremont, CA 000 000.00 000000000000 000.00
000000000 Venture Capital-Backed Coimbra, Portugal 0 00000 00000 00000 00000
You’re viewing 5 of 7 competitors. Get the full list »

Eyenuk Patents

Eyenuk Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20170039412-A1 Systems and methods for automated detection of regions of interest in retinal images Abandoned 22-Oct-2013 0000000000 0
US-20190042828-A1 Systems and methods for enhancement of retinal images Abandoned 22-Oct-2013 0000000000 0
US-20150110348-A1 Systems and methods for automated detection of regions of interest in retinal images Abandoned 22-Oct-2013 00000000000 00
US-20150110370-A1 Systems and methods for enhancement of retinal images Abandoned 22-Oct-2013 0000000000 0
US-9002085-B1 Systems and methods for automatically generating descriptions of retinal images Active 22-Oct-2013 G06T7/0014 0

Eyenuk Executive Team (2)

Name Title Board Seat Contact Info
Kaushal Solanki Ph.D Founder, Chief Executive Officer & Board Member
Frank Cheng President & CCO
To view Eyenuk’s complete executive team members history, request access »

Eyenuk Board Members (3)

Name Representing Role Since
Kaushal Solanki Ph.D Eyenuk Founder, Chief Executive Officer & Board Member 000 0000
Manish Potti Eyenuk Board Member 000 0000
You’re viewing 2 of 3 board members. Get the full list »

Eyenuk Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eyenuk Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AXA Investment Managers Asset Manager Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view Eyenuk’s complete investors history, request access »